Search Results for “NHS” – Page 20 – media

NICE flip-flops to back Bristol’s Opdivo in head and neck cancer despite data ‘uncertainties’

Back in April, England’s cost watchdogs said they wouldn’t cover Bristol-Myers Squibb’s Opdivo in head and neck cancer due to “uncertain” clinical evidence. Now, though, they’re singing a different tune.
- Source: Fiercepharm
- 552
- October 16, 2017
New Approvals NHS Opdivo
Ddu Attended Pharmed & Healthcare Vietnam 2017 and the China Dental Show 2017

The 17th Vietnam International Exhibition on products, equipment, medical supplies, pharmaceuticals and hospital & rehabilitation equipment is an important contributing activity in Vietnam hosted by the country’s Ministry of Health. The expo is annually organized by the ADPEX JOINT STOCK COMPANY in cooperation with the Central Health Communication & Education Centre, Vietnam Pharmaceutical Companies Association and VIMEDIMEX VN.
- Source: Ddu
- 877
- September 27, 2017
Exhibitions & Activities Pharmed & Healthcare Vietnam Vietnam
Europe’s first stem cell therapy backed by NICE

Chiesi's Holoclar, the first stem-cell therapy to be cleared by European regulators, has received a green light for use on the NHS in England and Wales to treat a rare sight condition.
- Source: pharmatimes
- 858
- August 29, 2017
New Approvals NHS stem-cell therapy
Atlas awarded £2m grant for infectious disease test

In support of the project in adopting Atlas Genetic's io rapid diagnostic platform into UK sexual health clinics, Innovative UK has awarded them a grant of £2 million.
- Source: news.open-medical
- 434
- August 16, 2017
Company Insight diagnostic infectious
NICE turns down kidney cancer drugs

It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will be getting routine NHS access to Eisai’s Kisplyx or Eusa Pharma’s Fotivda, after cost regulators issued draft guidelines turning down their use.
- Source: pharmatimes
- 518
- August 15, 2017
cancer kidney Market Views NHS renal
NICE backs new treatment option for psoriasis

The National Institute for Health and Care Excellence has issued draft guidelines backing NHS use of Almirall’s Skilarence to treat moderate to severe plaque psoriasis.
- Source: pharmatimes
- 521
- August 9, 2017
Company Insight New Approvals NHS NICE psoriasis
Fast-track pancreatic cancer surgery boosts success, saves money

Accelerating access to pancreatic surgery has been shown to boost success rates by more than a fifth with a cost saving to the NHS of around £3,200 per patient.
- Source: pharmatimes
- 410
- August 3, 2017
Clinical Trials NHS pancreatic
Diabetes prescriptions rocket 80 percent in a decade

Growth in prescriptions for diabetes medicines is exceeding the rise in overall prescribing, according to new figures from NHS Digital.
- Source: pharmatimes
- 556
- August 3, 2017
diabetes Market Views Researches
NICE u-turn backs use of Teva’s asthma biologic

The National Institute for Health and Care Excellence (NICE) is now backing routine NHS commissioning of Teva’s Cinqaero to treat a severe form of asthma after having initially been minded to block the drug’s use.
- Source: pharmatimes
- 466
- July 21, 2017
asthma New Approvals NICE
ABPI seeks to challenge NICE reforms in court

The Association of the British Pharmaceutical Industry is seeking to challenge in court new rules on appraising medicines for NHS use, insisting that the changes will hinder patient access to the latest medical innovations.
- Source: pharmatimes
- 799
- July 20, 2017
innovation Policy

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.